Fingerprint
Dive into the research topics of 'Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial
Eric J. Lenze, Caline Mattar, Charles F. Zorumski, Angela Stevens, Julie Schweiger, Ginger E. Nicol, J. Philip Miller, Lei Yang, Michael Yingling, Michael S. Avidan, Angela M. Reiersen
- Department of Psychiatry
- Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
- Institute of Clinical and Translational Sciences (ICTS)
- COVID-19 Researchers
- Division of Infectious Diseases
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Institute for Informatics, Data Science and Biostatistics (I2DB)
- Siteman Cancer Center
- Washington University School of Medicine
- Department of Anesthesiology
- Institute for Public Health
- DBBS - Neurosciences
- DBBS - Biochemistry, Biophysics, and Structural Biology
- Division of Child & Adolescent Psychiatry
- Hope Center for Neurological Disorders
- mHealth Research Core
- Intellectual and Developmental Disabilities Research Center (IDDRC)
- Division of Education
- Division of Basic Science Research
- Division of Clinical Neuroscience and Behavioral Health Research
- Center for Biostatistics and Data Science (CBDS)
Research output: Contribution to journal › Article › peer-review
426
Scopus
citations